PAUL NORWOOD: Open Payments
NPI 1871503649 · FRESNO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,537 in 62 payments from 22 companies in 2025. Trend: 2023 $2,135 · 2024 $1,498 · 2025 $1,537
Food & beverage: $1,537
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 6 | $208 |
| Novo Nordisk Inc | 10 | $203 |
| Lilly USA, LLC | 13 | $193 |
| Medtronic, Inc. | 8 | $185 |
| Neurocrine BioSciences, Inc. | 2 | $121 |
| Globus Medical, Inc. | 1 | $114 |
| KYOWA KIRIN, INC. | 3 | $79 |
| Averitas Pharma Inc. | 2 | $59 |
| Xeris Pharmaceuticals, Inc. | 3 | $59 |
| Lexicon Pharmaceuticals, Inc. | 1 | $40 |
Products named: MINIMED 780G, Ozempic, ETERNA, JARDIANCE, CRENESSITY, Senza, MOUNJARO, CRYSVITA.
Industry payments across CA — which companies pay providers there.
